相关实验视频

Updated: Jul 5, 2025

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

针对THBS1的Mir-338-3p通过抑制PI3K/Akt路径来减轻质瘤的进展

Lianglei Jiang¹, Ting Fang¹, Tingting Hu¹

¹Department of Neurosurgery, , Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , 430022, Wuhan, China.

|January 24, 2024

概括

微RNA-338-3p (miR-338-3p) 通过向血栓蛋白1 (THBS1) 和抑制PI3K/Akt通路来抑制质瘤的进展. 这个miR-338-3p/PI3K/Akt/THBS1轴为质瘤提供了潜在的治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生化学

背景情况:

质瘤是一种具有有限治疗选择的侵袭性脑瘤.
了解质瘤的分子驱动因素对于开发向疗法至关重要.
微RNA-338-3p (miR-338-3p) 在各种癌症中显示出抑制瘤生长的潜力.

研究的目的:

为了研究miR-338-3p/酸-3-激酶 (PI3K) /Akt/血小板蛋白1 (THBS1) 途径在质瘤进展中的调节作用.
阐明 miR-338-3p 对质瘤细胞行为影响的分子机制.

主要方法:

使用定量逆转录聚合酶链反应和西部涂抹来评估分子水平.
双露西法酶试验证实了miR-338-3p直接针对THBS1的情况.
在试验室进行了迁移和扩散测试,以及在小鼠体内瘤性研究.

主要成果:

在质瘤中,miR-338-3p的调控下降,而THBS1的表达则升高.
miR-338-3p通过抑制PI3K/Akt信号通路来抑制质瘤细胞迁移和增殖.
过度表达THBS1促进了质瘤的进展,这种效应被miR-338-3p抵消了.

结论:

在miR-338-3p/PI3K/Akt/THBS1调节轴显著调节质瘤细胞的增殖和迁移.
这一途径代表了治疗质瘤治疗的有前途的治疗生物标志物.

关键词:

质瘤是一种质瘤.在PI3K/Akt.在THBS1中,THBS1是THBS1.在 miR-338-3p 中使用.

更多相关视频

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...